Identification of ∆9-tetrahydrocannabinol (THC) impairment using functional brain imaging

Jodi M Gilman, William A Schmitt, Kevin Potter, Brian Kendzior, Gladys N Pachas, Sarah Hickey, Meena Makary, Marilyn A Huestis, A Eden Evins, Jodi M Gilman, William A Schmitt, Kevin Potter, Brian Kendzior, Gladys N Pachas, Sarah Hickey, Meena Makary, Marilyn A Huestis, A Eden Evins

Abstract

The primary cannabinoid in cannabis, Δ9-tetrahydrocannabinol (THC), causes intoxication and impaired function, with implications for traffic, workplace, and other situational safety risks. There are currently no evidence-based methods to detect cannabis-impaired driving, and current field sobriety tests with gold-standard, drug recognition evaluations are resource-intensive and may be prone to bias. This study evaluated the capability of a simple, portable imaging method to accurately detect individuals with THC impairment. In this double-blind, randomized, cross-over study, 169 cannabis users, aged 18-55 years, underwent functional near-infrared spectroscopy (fNIRS) before and after receiving oral THC and placebo, at study visits one week apart. Impairment was defined by convergent classification by consensus clinical ratings and an algorithm based on post-dose tachycardia and self-rated "high." Our primary outcome, prefrontal cortex (PFC) oxygenated hemoglobin concentration (HbO), was increased after THC only in participants operationalized as impaired, independent of THC dose. ML models using fNIRS time course features and connectivity matrices identified impairment with 76.4% accuracy, 69.8% positive predictive value (PPV), and 10% false-positive rate using convergent classification as ground truth, which exceeded Drug Recognition Evaluator-conducted expanded field sobriety examination (67.8% accuracy, 35.4% PPV, and 35.4% false-positive rate). These findings demonstrate that PFC response activation patterns and connectivity produce a neural signature of impairment, and that PFC signal, measured with fNIRS, can be used as a sole input to ML models to objectively determine impairment from THC intoxication at the individual level. Future work is warranted to determine the specificity of this classifier to acute THC impairment.ClinicalTrials.gov Identifier: NCT03655717.

Conflict of interest statement

JMG and AEE reported having a patent pending (WO 2018/027151) to use fNIRS to measure intoxication. BK received funds from a NIH STTR grant to Highlight-I to conduct the ML analyses. MAH reported scientific advising/consulting for PinneyAssociates, Cannabix, the Canadian Nuclear Safety Commission, Nextage Therapeutics, Suncor Energy, and Dynacare Laboratories. All other authors declare they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1. Design of probe and machine…
Fig. 1. Design of probe and machine learning models.
A The continuous wave near-infrared spectroscopy (NIRS) machine was used to measure changes in oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (deoxy-Hb). The NIRS probe comprised of eight sources (red) and seven detectors (yellow) placed over the prefrontal brain region (forehead) of each participant. The mid-column of the probe was placed over Fpz, with the lowest probes located along the F5-Fp1-Fpz-Fp2-F6 line, in accordance with the International 10–20 Placement System. The distance between pairs of source and detector probes ranged from 2.5 - 3 cm. The midpoint of the source-detector distance was defined as channel (Ch) location, labeled numerically (1–20) in the above schematic. The channels were grouped into regions of interest, as illustrated in the schematic. We defined five regions on interest (ROIs) based on channel location. These ROIs are middle prefrontal cortex (MPFC, channels 7, 8, 9, 10, 11, 12, 13, 14); right dorsolateral prefrontal cortex (RDLPFC, channels 15, 17, 18); right ventrolateral prefrontal cortex (RVLPFC, channels 16, 19, 20); left dorsolateral prefrontal cortex (LDLPFC, channels 1, 2, 5); and left ventrolateral prefrontal cortex (LVLPFC, channels 3, 4, 6). B We extracted 95 numerical values (19 from each of the 5 ROIs): mean HbO values for time segments 0–5, 5–10, 10–15, 15–20, 20–25, 25–30, 30–35, and 35–40 s, slope (5–15 s), skewness (0–15 s), kurtosis (0–15 s), area under the curve (0–15, 15–40 s), time to first and second extremum of HbO, magnitude of first and second extremum of HbO, and average and standard deviation of HbO after the first extremum. We used these 95 predictive features to train XGBoost to predict impairment. C We computed pairwise correlations between the HbO concentration change values of all possible channel pairs. We computed dynamic connectivity matrices with sliding windows of 300 time points, and a skip of 100 time points, so that each window corresponded to a small segment of the scan. We then trained an RNN model architecture with the sliding-window correlation matrix feature vector as the input. In this RNN, the core component consisted of fully connected layers that mapped the input to a latent representation, which in turn fed to a hidden state with recurrent connections. A probabilistic prediction was computed at every time point by applying a fully connected layer to the hidden state. We used tanh for all nonlinearities and implemented a fully connected neural network with 5 hidden layers and 128, 64, 32, and 16 nodes. The output of this model was a fully connected neural net with a single hidden layer of 64 dimensions and consisted of recurrent connections that captured temporal dynamics.
Fig. 2. Psychological and physiological measures of…
Fig. 2. Psychological and physiological measures of participants by impairment and drug status.
A Participants were assessed for impairment via an algorithmic approach and a clinical approach into “Impaired” and “Not Clearly Impaired” groupings, which were then used to build and test a classifier for impairment using fNIRS data. B Time course of A self-reported high (0–100 scale to answer the question: “Are you high right now?”, 0 being “Not at all” and 100 being “Extremely”) and B heart rate (beats per minute) were averaged over (1) individuals identified as impaired post-THC by consensus ratings (red triangles), (2) individuals identified as not clearly impaired post-THC by concordant ratings (black triangles), and (3) all individuals post-placebo (filled circles). Impairment status post-THC was determined based on concordant ratings between two rating methods, algorithmic and clinical experts. Error bars are 95% confidence intervals for the mean generated via bootstrap. Gray bars show time windows for the pre-dose (Scan 1) and post-dose (Scans 2 and 3) fNIRS imaging.
Fig. 3. HbO response at pre- and…
Fig. 3. HbO response at pre- and post-dose by consensus rating (columns 1 and 2), placebo (column 3) and eFSR rating (columns 4 and 5).
The time course of mean HbO changes (µM) in each ROI are plotted in those who received THC and were impaired (Col 1), received THC and were unimpaired (Col 2), received placebo THC (Col 3), received an impaired rating from an eFST (Col 4), and in those who received a not-impaired rating from an eFST (Col 5). Pre-dose HbO response is shown in blue, and peak dose (Scan 2 or 3, whichever had the higher intoxication rating) is shown in red. Blue and red lines represent the mean and the standard error of the mean in each group. Yellow lines represent single timepoints in which the group differences between pre and peak HbO were significant (using a paired t-test with Benjamini-Hochberg FDR correction and p < 0.05). For statistical purposes, only matched pre and post-dose scans were included, which resulted in a sample size of 77 (out of 80) concordant impaired subjects and 55 (out of 57) concordant not clearly impaired subjects. MPFC middle prefrontal cortex, RDLPFC right dorsolateral prefrontal, RVLPFC right ventrolateral prefrontal cortex, LDLPFC left dorsolateral prefrontal cortex, and LVLPFC left ventrolateral prefrontal cortex.
Fig. 4. Machine learning metrics.
Fig. 4. Machine learning metrics.
A TS, time series, CONN, connectivity, eFST, extended field sobriety test. B Receiver operative characteristic (ROC) curve for combined fNIRS models.

References

    1. Compton R. Vol. DOT HS 812 440. Washington, DC: National Highway Traffic Safety Administration; 2017.
    1. Huestis MA. Cannabis-impaired driving: a public health and safety concern. Clin Chem. 2015;61:1223–5.
    1. Arkell TR, Spindle TR, Kevin RC, Vandrey R, McGregor IS. The failings of per se limits to detect cannabis-induced driving impairment: results from a simulated driving study. Traffic Inj Prev. 2021;22:102–07.
    1. Madras BK. Are THC levels in oral fluids and blood plasma comparable after oral ingestion of edibles containing cannabis or THC? Clin Chem. 2017;63:629–31.
    1. Newmeyer MN, Swortwood MJ, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. Cannabis edibles: blood and oral fluid cannabinoid pharmacokinetics and evaluation of oral fluid screening devices for predicting delta9-tetrahydrocannabinol in blood and oral fluid following cannabis brownie administration. Clin Chem. 2017;63:647–62.
    1. The International Association of Chiefs of Police (ICAP) and the National Highway Traffic Safety Administration (NHTSA). Advanced Roadside Impaired Driving Enforcement (ARIDE). R5/13 Edition Participant Manual. 2018.
    1. Bosker WM, Kuypers KP, Theunissen EL, Surinx A, Blankespoor RJ, Skopp G, et al. Medicinal Delta(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction. 2012;107:1837–44.
    1. Yoshizuka K, Perry PJ, Upton G, Ip EJ. Standardized field sobriety test: False positive test rate among sober subjects. J Forensic Toxicol Pharmacol. 2014;3:120.
    1. Dillow C. How Will Police Regulate Stoned Driving? Popular science. Published Jun 5. 2013. .
    1. Markus B. The Difficulty Of Enforcing Laws Against Driving While High NPR. Ben Markus, Colorado Public Radio. NPR Published September 6, 2016.
    1. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex. 2007;17:175–91.
    1. Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Delta(9)-tetrahydrocannabinol on the dopamine system. Nature. 2016;539:369–77.
    1. Mason NL, Theunissen EL, Hutten N, Tse DHY, Toennes SW, Stiers P, et al. Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity. Eur Neuropsychopharmacol. 2019;29:247–56.
    1. Ramaekers JG, Mason NL, Theunissen EL. Blunted highs: pharmacodynamic and behavioral models of cannabis tolerance. Eur Neuropsychopharmacol. 2020;36:191–205.
    1. Ramaekers JG, van Wel JH, Spronk D, Franke B, Kenis G, Toennes SW, et al. Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes. Brain Imaging Behav. 2016;10:1254–63.
    1. Crane NA, Funkhouser CJ, Burkhouse KL, Klumpp H, Phan KL, Shankman SA. Cannabis users demonstrate enhanced neural reactivity to reward: an event-related potential and time-frequency EEG study. Addict Behav. 2021;113:106669.
    1. van Hell HH, Jager G, Bossong MG, Brouwer A, Jansma JM, Zuurman L, et al. Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology. 2012;219:981–90.
    1. Gilman JM, Yucel MA, Pachas GN, Potter K, Levar N, Broos H, et al. Delta-9-tetrahydrocannabinol intoxication is associated with increased prefrontal activation as assessed with functional near-infrared spectroscopy: A report of a potential biomarker of intoxication. Neuroimage. 2019;197:575–85.
    1. Keles HO, Radoman M, Pachas GN, Evins AE, Gilman JM. Using functional near-infrared spectroscopy to measure effects of delta 9-tetrahydrocannabinol on prefrontal activity and working memory in cannabis users. Front Hum Neurosci. 2017;11:488.
    1. Yang D, Huang R, Yoo S-H, Shin M-J, Yoon JA, Shin Y-I, et al. Detection of mild cognitive impairment using convolutional neural network: temporal-feature maps of functional near-infrared spectroscopy. Front. Aging Neurosci. 2020;12.
    1. Wang Y, Lin K, Qi Y, Lian Q, Feng S, Wu Z, et al. Estimating brain connectivity with varying-length time lags using a recurrent neural network. IEEE Trans Biomed Eng. 2018;65:1953–63.
    1. Schlienz NJ, Lee DC, Stitzer ML, Vandrey R. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. Drug Alcohol Depend. 2018;187:254–60.
    1. Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-carboxy-delta9-tetrahydrocannabinol in humans. Ther Drug Monit. 1998;20:570–6.
    1. Morean ME, de Wit H, King AC, Sofuoglu M, Rueger SY, O’Malley SS. The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology. 2013;227:177–92.
    1. Maki A, Yamashita Y, Ito Y, Watanabe E, Mayanagi Y, Koizumi H. Spatial and temporal analysis of human motor activity using noninvasive NIR topography. Med Phys. 1995;22:1997–2005.
    1. Cope M, Delpy DT. System for long-term measurement of cerebral blood and tissue oxygenation on newborn infants by near infra-red transillumination. Med Biol Eng Comput. 1988;26:289–94.
    1. Homan RW, Herman J, Purdy P. Cerebral location of international 10-20 system electrode placement. Electroencephalogr Clin Neurophysiol. 1987;66:376–82.
    1. Huppert TJ, Diamond SG, Franceschini MA, Boas DA. HomER: a review of time-series analysis methods for near-infrared spectroscopy of the brain. Appl Opt. 2009;48:D280–98.
    1. Yang D, Huang R, Yoo SH, Shin MJ, Yoon JA, Shin YI, et al. Detection of mild cognitive impairment using convolutional neural network: temporal-feature maps of functional near-infrared spectroscopy. Front Aging Neurosci. 2020;12:141.
    1. Abbasvandi Z, Nasrabadi AM. A self-organized recurrent neural network for estimating the effective connectivity and its application to EEG data. Comput Biol Med. 2019;110:93–107.
    1. Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR, Coleman RE. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand. 1999;100:67–75.
    1. Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry. 2003;160:709–19.
    1. Manoach DS. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res. 2003;60:285–98.
    1. Cribben I, Haraldsdottir R, Atlas LY, Wager TD, Lindquist MA. Dynamic connectivity regression: determining state-related changes in brain connectivity. Neuroimage. 2012;61:907–20.
    1. Thompson GJ, Magnuson ME, Merritt MD, Schwarb H, Pan WJ, McKinley A, et al. Short-time windows of correlation between large-scale functional brain networks predict vigilance intraindividually and interindividually. Hum Brain Mapp. 2013;34:3280–98.
    1. Chang C, Metzger CD, Glover GH, Duyn JH, Heinze HJ, Walter M. Association between heart rate variability and fluctuations in resting-state functional connectivity. Neuroimage. 2013;68:93–104.
    1. Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, et al. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology. 2019;236:2713–24.
    1. Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, et al. Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol. 2017;41:83–99.
    1. O’Connor S, Morzorati S, Christian J, Li TK. Clamping breath alcohol concentration reduces experimental variance: application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcohol Clin Exp Res. 1998;22:202–10.
    1. Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5:1–8.
    1. Schlienz NJ, Spindle TR, Cone EJ, Herrmann ES, Bigelow GE, Mitchell JM, et al. Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. Drug Alcohol Depend. 2020;211:107969.
    1. Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, et al. Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: a crossover trial. JAMA Netw Open. 2018;1:e184841.
    1. Spindle TR, Martin EL, Grabenauer M, Woodward T, Milburn MA, Vandrey R. Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. J Psychopharmacol. 2021;35:786–803.
    1. Richman J, May S. An Investigation of the Druid® smart- phone/tablet app as a rapid screening assessment for cognitive and psychomotor impairment associated with alcohol intoxication. Vis Dev Rehab. 2019;19:31–42.
    1. Pinti P, Tachtsidis I, Hamilton A, Hirsch J, Aichelburg C, Gilbert S, et al. The present and future use of functional near-infrared spectroscopy (fNIRS) for cognitive neuroscience. Ann N Y Acad Sci. 2020;1464:5–29.
    1. Pinti P, Aichelburg C, Lind F, Power S, Swingler E, Merla A, et al. Using fiberless, wearable fNIRS to monitor brain activity in real-world cognitive tasks. J Vis Exp. 2015.
    1. Lloyd-Fox S, Blasi A, Elwell CE. Illuminating the developing brain: the past, present and future of functional near infrared spectroscopy. Neurosci Biobehav Rev. 2010;34:269–84.
    1. Balardin JB, Zimeo Morais GA, Furucho RA, Trambaiolli L, Vanzella P, Biazoli C, Jr., et al. Imaging brain function with functional near-infrared spectroscopy in unconstrained environments. Front Hum Neurosci. 2017;11:258.
    1. McKendrick R, Parasuraman R, Murtza R, Formwalt A, Baccus W, Paczynski M, et al. Into the wild: neuroergonomic differentiation of hand-held and augmented reality wearable displays during outdoor navigation with functional near infrared spectroscopy. Front Hum Neurosci. 2016;10:216.
    1. Pinti P, Cardone D, Merla A. Simultaneous fNIRS and thermal infrared imaging during cognitive task reveal autonomic correlates of prefrontal cortex activity. Sci Rep. 2015;5:17471.
    1. Gagnon L, Cooper RJ, Yucel MA, Perdue KL, Greve DN, Boas DA. Short separation channel location impacts the performance of short channel regression in NIRS. Neuroimage. 2012;59:2518–28.
    1. Richman J. An investigation of the Druid® smartphone/tablet app as a rapid screening assessment for cognitive and psychomotor impairment associated with alcohol intoxication. Vis Dev Rehab. 2019;5.

Source: PubMed

3
Abonneren